4599.TStemRIM
The schedule
- Mon14Sep
StemRIM's FY2026 annual financial results. At 52-week highs and an overbought RSI of 71.5, market focus centers on the expected REvive trial timeline. Profit-taking is the base case.
- Fri20Nov
Highly anticipated topline read from the Shionogi-partnered REvive Phase 2b trial of Redasemtide (S-005151) for acute ischemic stroke. Success derisks a massive total addressable market.
- Mon14Dec
- Mon15Mar
Q2 FY2027 results. Despite sufficient current runway, biotech capital structure risks heighten as management may elect to raise funds at elevated valuations.
- Tue20Apr
Topline readout from the Phase 1/2 clinical trial evaluating Redasemtide in patients with ischemic cardiomyopathy, testing the broader platform utility.
- Mon14Jun
Q3 FY2027 earnings release. Market anticipation centers on updates regarding out-licensing activities for next-generation candidates TRIM3 and TRIM4.
- Tue20Jul
Expected regulatory update jointly announced with Shionogi regarding the PMDA filing strategy and potential accelerated approval for Redasemtide in Japan.
